いまさら訊けない！　がん支持療法Ｑ＆Ａ

出版社： 中外医学社
著者：
発行日： 2018-06-20
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784498022669
電子書籍版： 2018-06-20 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,180 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,180 円(税込)

購入する

商品紹介

いまや，がんは2人に1人が罹患するcommon disease．すべての医療スタッフが日常的にがん患者さんと接する時代です．がん治療を安全かつ効果的に実施するためのがん支持療法は，一般内科医はもちろん，医療現場で活躍する人全員が造詣を深めるべきテーマです．本書では代表的な支持療法につき，Q&Aでエキスパートがわかりやすく解説します！

目次

  • I　がん治療時に遭遇しやすい問題：栄養管理
    　Q1．がん患者の栄養評価はどうすればよいですか？
    　Q2．がん患者の栄養療法はどうすればよいですか？
    　Q3．外来化学療法中の栄養管理はどうすればよいですか？
    　Q4．がん患者のサルコペニア，フレイルについて教えてください
    　Q5．がん悪液質に対する栄養療法はどうすればよいですか？
    　Q6．上部消化器がん術後の栄養管理はどうしたらよいですか？
    　Q7．がん治療時の口腔ケアはどうすればよいですか？
    　Q8．がん治療時の悪心・嘔吐のマネジメントを教えてください

    II　がん治療時に遭遇しやすい問題：感染対策
    　Q1．どんなときにカテーテル関連血流感染症を疑えばよいですか？　
    　　　　また，抗菌薬の使いかたについて教えてください
    　Q2．発熱性好中球減少症のマネジメントについて教えてください
    　Q3．難治性の下痢の場合，どういった感染症を疑えばよいですか？
    　Q4．抗がん剤による間質性肺炎と呼吸器感染の鑑別はどのようにすればよいですか？　
    　Q5．がん化学療法におけるB型肝炎ウイルスの再活性化はどう評価して対策すればよいですか？
    　Q6．リンパ浮腫による蜂窩織炎はどう対処すればよいですか？
    　Q7．周術期や放射線・化学療法中・後の嚥下障害に関して，誤嚥性肺炎を予防しスムーズに
    　　　　経口摂取を獲得するためには，どうすればよいですか？

    III　がん治療時に遭遇しやすい問題：腎・内分泌・代謝
    　Q1．急性腎障害を発症しやすい抗がん剤はどれですか？
    　　　　抗がん剤による急性腎障害を予防するにはどうしたらよいですか？
    　Q2．造影剤腎症を予防するにはどうしたらよいですか？
    　Q3．血液透析患者への抗がん剤投与はどうしたらよいですか？
    　Q4．腫瘍崩壊症候群の予防と治療はどうすればよいですか？
    　Q5．低ナトリウム血症はどう補正したらよいですか？
    　Q6．高カルシウム血症の臨床像と治療法を教えてください　
    　Q7．がん治療が必要な糖尿病患者の血糖管理は　どうすればよいですか？
    　Q8．がん患者にみられる低血糖の鑑別法と治療法について教えてください

    IV　がん治療時に遭遇しやすい問題：その他
    　Q1．がん治療時に循環器疾患を有する場合，
    　　　　がん治療においてどのような点に注意が必要ですか？
    　Q2．がん治療時にみられやすい意識障害の診断法と治療はどうすればよいですか？
    　Q3．がん患者の血栓塞栓症について，疫学，診断法，対処法について教えてください
    　Q4．トルソー症候群とはどういった病態ですか？　またどう対処すればよいですか？
    　Q5．がん治療時の精神症状の評価法と治療について教えてもらえますか？
    　Q6．むずむず脚症候群の診断と治療はどうすればよいですか？

    V　がん治療後の問題
    　Q1．急性腎障害患者の長期フォローアップはどうすればよいですか？
    　Q2．がん治療時の骨粗鬆症はどう評価し治療すればよいですか？
    　Q3．抗がん剤治療後の認知機能低下（ケモブレイン）とはどういった病態ですか？
    　　　　また，どう対応すればよいですか？
    　Q4．抗がん剤治療後にみられやすい心不全について教えてください
    　Q5．化学療法後の女性の妊孕性について教えてもらえますか？
    　Q6．抗がん剤治療後の末梢神経障害について，対処法も含めて教えてください
    　Q7．がん患者にみられる悪性大静脈症候群とはどんな病態ですか？
    　Q8．がん治療後のうつ病やストレス障害について教えてください
    　Q9．がん治療後にみられるリンパ浮腫の評価法と対処法に　ついて教えてください

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] がん治療時に遭遇しやすい問題 : 栄養管理

P.7 掲載の参考文献
1) 奥川喜永, 白井由美子, McMillan DC, 他. がん治療と栄養評価. 日静脈経腸栄会誌. 2017 ; 32 : 829-40.
 
2) Forrest LM, McMillan DC, McArdLe CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable nonsmall-cell lung cancer. Br J Cancer. 2003 ; 89 : 1028-30.
PubMed
3) Toiyama Y, Miki C, Inoue Y, et al. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med.2011 ; 2 : 95-101.
PubMed
4) Inoue Y, Iwata T, Okugawa Y, et al. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology. 2013 ; 84 : 100-7.
PubMed
5) 小野寺時夫, 五関謹秀, 神前五郎. Stage IV, V (Vは大腸癌) 消化器癌の非治療切除・姑息手術に対するTPNの適応と限界. 日外会誌. 1984 ; 85 : 1001-5.
 
6) Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011 ; 98 : 268-74.
PubMed
7) Kanda M, Mizuno A, Tanaka C, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine. 2016 ; 95 : e3781.
PubMed
8) Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, et al. CONUT : a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005 ; 20 : 38-45.
 
9) Toyokawa T, Kubo N, Tamura T, et al. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma : results from a retrospective study. BMC Cancer. 2016 ; 16 : 722.
PubMed
10) Iseki Y, Shibutani M, Maeda K, et al. Impact of the Preoperative Controlling Nutritional Status (CONUT) Score on the Survival after Curative Surgery for Colorectal Cancer. PloS One. 2015 ; 10 : e0132488.
PubMed
11) Gonzalez Madrono A, Mancha A, Rodriguez FJ, et al. The use of biochemical and immunological parameters in nutritional screening and assessment. Nutr Hosp. 2011 ; 26 : 594-601.
PubMed
12) Toiyama Y, Yasuda H, Ohi M, et al. Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. Am J Surg. 2017 ; 213 : 120-6.
PubMed
13) Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980 ; 139 : 160-7.
PubMed
14) 谷口正哲, 沢井博純, 小林勝正, 他. がん治療と栄養療法-最近の話題から. 静脈経腸栄養. 2013 ; 28 : 591-5.
 
15) 山田陽介, 山本和義, 永妻佑季子, 他. サルコペニアを知ろう! 消化器外科. 2017 ; 40 : 1009-87.
 
16) 濱口哲也, 三木誓雄. がん患者の代謝と栄養. 日静脈経腸栄会誌. 2015 ; 30 : 911-6.
 
17) McMillan DC. The systemic inflammation-based Glasgow Prognostic Score : a decade of experience in patients with cancer. Cancer Treat Rev. 2013 ; 39 : 534-40.
 
18) Shirai Y, Okugawa Y, Hishida A, et al. Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep. 2017 ; 7 : 4826.
PubMed
P.13 掲載の参考文献
1) Ramos EJ, Suzuki S. Marks D, et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care. 2007 ; 7 : 427-34.
 
2) Simons JP, Schols AM, Buurman WA, et al. Weight loss and low body cell mass in males with lung cancer : relationship with systemic inflammation, acutephase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond).1999 ; 97 : 215-23.
PubMed
3) Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 ; 69 : 491-7.
 
4) Pedersen H, Hansen HS, Cederqvist C, et al. The prognostic significance of weight loss and its integration in stage-grouping of oesophageal cancer. Acta Chir Scand. 1982 ; 148 : 363-6.
PubMed
5) Bachmann J, Heiligensetzer T, Krakowski-Roosein H, et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008 ; 12 : 1193-201.
 
6) Bozzetti F, Arends J, Lundholm K, et al. ESPEN Guidelines on Parenteral Nutrition : non-surgical oncology. Clin Nutr. 2009 ; 28 : 445-54.
PubMed
7) Bosaeus I, Daneryd P, Svanberg E, et al. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001 ; 93 : 380-3.
PubMed
8) Knox LS, Crosby LO, Feurer ID, et al. Energy expenditure in malnourished cancer patients. Ann Surg. 1983 ; 197 : 152-62.
PubMed
9) Fredrix EW, Soeters PB, Wouters EF, et al. Effect of different tumor types on resting energy expenditure. Cancer Res. 1991 ; 51 : 6138-41.
PubMed
10) Staal-van den Brekel AJ, Schols AM, Dentener MA, et al. The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma. Br J Cancer. 1997 ; 76 : 1630-5.
PubMed
11) Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 ; 36 : 11-48.
PubMed
12) Bozzetti F, Mori V. Nutritional support and tumour growth in humans : A narrative review of the literature. Clinical Nutrition. 2009 ; 28 : 226-30.
PubMed
13) Tijerina AJ. The biochemical basis of metabolism in cancer cachexia. Dimens. Crit. Care Nurs. 2004 ; 23 : 237-43.
PubMed
14) Nitenberg G, Raynard B. Nutritional support of the cancer patient : Issues and dilemmas. Critical Reviews in Oncology/Hematology. 2000 ; 34 : 137-68.
PubMed
15) Baracos VE. Meeting the amino acid requirements for protein anabolism in cancer cachexia. In : Mantovani G, Anker SD, Inui A, et al. Cachexia and wasting : a modern approach. Springer-Verlag Mailand ; 2003. p.631-4.
 
16) Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr. 2012 ; 31 : 765-73.
PubMed
17) Baracos VE. Skeletal muscle anabolism in patients with advanced cancer. The Lancet Oncology. 2015 ; 16 : 13-4.
PubMed
18) Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia : a randomised double blind trial. Gut. 2003 ; 52 : 1479-86.
PubMed
19) Silva J de A, Trindade EB, Fabre ME, et al. Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients. Nutr Cancer. 2012 ; 64 : 267-73.
PubMed
20) van der Meij BS, Langius JA, Spreeuwenberg MD, et al. Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment : an RCT. Eur J Clin Nutr. 2012 ; 66 : 399-404.
PubMed
21) Sanchez-Lara K, Turcoff JG, Juarez-Hernandez E, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer : randomised trial. Clin Nutr. 2014 ; 33 : 1017-23.
 
22) Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006 ; 24 : 3401-7.
PubMed
23) Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting : a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004 ; 22 : 2469-76.
PubMed
24) Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2017 ; CD004597. doi : 10.1002/14651858. CD004597. pub2.
 
25) Mazzotta P, Jeney CM. Anorexia-cachexia syndrome : a systematic review of the role of dietary polyunsaturated Fatty acids in the management of symptoms, survival, and quality of life. J Pain Symptom Manage. 2009 ; 37 : 1069-77.
PubMed
26) de Aguiar Pastore Silva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and/or radiotherapy : A systematic review. Clinical Nutrition. 2015 ; 34 : 359-66.
PubMed
27) May PE, Barber A, D'Olimpio JT, et al. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am J Surg. 2002 ; 183 : 471-9.
 
28) Deutz NE, Safar A, Schutzler S, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr. 2011 ; 30 : 759-68.
PubMed
29) Alexander JW, Saito H, Trocki O, et al. The importance of lipid type in the diet after burn injury. Ann Surg. 1986 ; 204 : 1-8.
PubMed
30) Schwab JM, Chiang N, Arita M, et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007 ; 447 : 869-74.
PubMed
31) Rose DP, Connolly JM. Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol. 1999 ; 15 : 1011-5.
PubMed
32) Siddiqui RA, Jenski LJ, Neff K, et al. Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. Biochim Biophys Acta. 2001 ; 1499 : 265-75.
PubMed
P.20 掲載の参考文献
1) 安武健一郎, 山内健, 江角誠, 他. 入院時栄養スクリーニングを構成する各栄養評価指標に対する解析. 栄養評価と治療. 2006 ; 23 : 561-5.
 
2) Neelemaat F, Kruizenga HM, de Vet HC, et al. Screening malnutrition in hospital outpatients. Can the SNAQ malnutrition screening tool also be applied to this population? Clin Nutr. 2008 ; 27 : 439-46.
PubMed
3) Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatirnts and inpatients : prevalence, concurrent validity and ease of the malnutrition universal screening tool (MUST) for adults. Br J Nutr. 2004 ; 92 : 799-808.
PubMed
4) 三浦あゆみ, 辻仲利政, 今西健二, 他. 外来化学療法患者における栄養障害患者の存在 : 簡易栄養評価法を用いた検討. 静脈経腸栄養. 2010 ; 25 : 603-7.
 
5) 田河みゆき, 名徳倫明, 岩本千晶, 他. 外来化学療法施行中の大腸がん患者に対するMalnutrition Universal Screening Tool (MUST) を用いた栄養評価. 癌と化学療法. 2013 ; 40 : 1185-8.
Medical*Online
6) 柴田裕, 伽羅谷千加子, 斉藤円, 他. 消化器癌外来化学療法患者に対する栄養サポートの試みとその効果の検討. 静脈経腸栄養. 2014 ; 29 : 1043-9.
 
7) 天野良亮, 花山佳子, 清水久実代, 他. 外来化学療法患者に対する栄養管理. 日静脈経腸栄会誌. 2017 ; 32 : 817-21.
 
P.28 掲載の参考文献
1) Rosenberg IH. Summary comments. Am J Clin Nutr. 1989 ; 50 : 1231-3.
 
2) Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People. Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010 ; 39 : 412-23.
 
3) Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia : consensus report of the asian working group for sarcopenia. J Am Med Dir Assoc. 2014 ; 15 : 95-101.
 
4) Moldawer LL, Copeland EM. Proinflammatory cytokines, nutritional support, and the cachexia syndrome interactions and therapeutic options. Cancer. 1987 ; 79 : 1828-39.
 
5) Yeh CW, Chen YJ, Lai Ly, et al. Bioelectrical impedance analysis in a mathematical model for estimating fat-free mass in multiple segments in elderly Taiwanese males. Int J Gerontol. 2012 ; 6 : 273-7.
 
6) Hamaguchi Y, Kaido T, Okumura S, et al. Proposal for new diagnostic criteria for low skeletal mass based on computed tomography imaging in Asian adults. Nutrition. 2016 ; 32 : 1200-5.
PubMed
7) Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumors of the respiratory and gastrointestinal tracts : a population-based study. Lancet Oncol. 2008 ; 9 : 629-35.
PubMed
8) Nishikawa H, Shiraki M, Hiramatsu A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition) : recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016 ; 46 : 951-63.
 
9) Hodari A, Hammoud ZT, Borgi JF, et al. Assessment of morbidity and mortality after esophagectomy using a modified frailty index. Ann Thorac Surg. 2013 ; 96 : 1240-5.
PubMed
10) Huang DD, Chen XX, Chen XY, et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer : a prospective study. J Cancer Res Clin Oncol. 2016 ; 142 : 2347-56.
PubMed
11) Fukuda Y, Yamamoto K, Hirao M, et al. Prevalence of malnutrition among gastric cancer patients undergoing gastrectomy and optimal preoperative nutritional support for preventing surgical site infections. Ann Surg Oncol. 2015 ; 22 : S778-85.
PubMed
12) Okumura S, Kaido T, Hamaguchi Y, et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015 ; 157 : 1088-98.
PubMed
13) Hamaguchi Y, Kaido T, Okumura S, et al. Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2015 ; 22 : 475-85.
PubMed
14) Hamaguchi Y, Kaido T, Okumura S, et al. Muscle steatosis is an independent predictor of postoperative complications in patients with hepatocellular carcinoma. World J Surg. 2016 ; 40 : 1959-68.
PubMed
15) Kobayashi A, Kaido T, Hamaguchi Y, et al. The impact of postoperative changes in sarcopenia factors on outcomes after for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2016 ; 23 : 57-64.
PubMed
16) Okumura S, Kaido T, Hamaguchi Y, et al. Impact of preoperative quality and quantity of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery. 2016 ; 159 : 821-33.
 
17) Okumura S, Kaido T, Hamaguchi Y, et al. Impact of skeletal muscle mass, muscle quality, and visceral adiposity on outcomes following resection of intrahepatic cholanginoma. Ann Surg Oncol. 2017 ; 24 : 1037-45.
PubMed
18) Okumura S, Kaido T, Hamaguchi Y, et al. Visceral adiposity and sarcopenic visceral obesity are associated with poor prognosis after resection of pancreatic cancer. Ann Surg Oncol. 2017 ; 24 : 3732-40.
PubMed
P.40 掲載の参考文献
1) Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol. 2003 ; 1 : 159-68.
PubMed
2) Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia : an international consensus. Lancet Oncol. 2011 ; 12 : 489-95.
PubMed
3) Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015 ; 33 : 90e9.
PubMed
4) Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 ; 36 : 11-48.
PubMed
P.47 掲載の参考文献
1) Doki Y, Takachi K, Ishikawa O, et al. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery. 2006 ; 139 : 797-805.
PubMed
2) Takiguchi N, Takahashi M, Ikeda M, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45) : a nationwide multi-institutional study. Gastric Cancer. 2015 ; 18 : 407-16.
PubMed
3) Imamura H, Nishikawa K, Kishi K, et al. Effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients : a randomized controlled clinical trial. Ann Surg Oncol. 2016 ; 23 : 2928-35.
PubMed
4) Kobayashi D, Ishigure K, Mochizuki Y, et al. Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301). Gastric Cancer. 2017 ; 20 : 718-27.
PubMed
5) Ohkura Y, Haruta S, Tanaka T, et al. Effectiveness of postoperative elemental diet (ElentalR) in elderly patients after gastrectomy. World J Surg Oncol. 2016 ; 14 : 268.
 
6) Shinohara T, Fujita T, Suzuki Y, et al. Interim results of nutritional support through a button-type jejunostomy after total gastrectomy. Am Surg. 2009 ; 75 : 148-51.
PubMed
7) Miyata H, Yano M, Yasuda T, et al. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. Clin Nutr. 2012 ; 31 : 330-6.
PubMed
8) Aoyama T, Yoshikawa T, Shirai J, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013 ; 20 : 2000-6.
PubMed
P.54 掲載の参考文献
1) 坪佐恭宏, 佐藤弘, 大曲貴夫, 他. 食道癌に対する開胸開腹食道切除再建術における術後肺炎予防. 日外感染症会誌. 2006 ; 3 : 43-7.
Medical*Online
2) 大田洋二郎. 口腔ケア介入は頭頸部進行癌における再建手術の術後合併症率を減少させる-静岡県立がんセンターにおける挑戦-. 歯界展望. 2005 ; 106 : 766-72.
 
3) Dreizen S, Daly TE, Drane JB, et al. Oral complications of cancer radiotherapy. Postgr Med. 1977 ; 61 : 85-92.
 
4) Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002 ; 28 : 65-74.
PubMed
5) Morrish RB, Chan E, Silverman S, et al. Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer. 1981 ; 47 : 1980-3.
PubMed
6) 米田俊之, 萩野浩, 杉本利嗣, 他. 骨吸収抑制薬関連顎骨壊死の病態と管理 : 顎骨壊死検討委員会ポジションペーパー 2016.
 
7) de Oliveira MA, Martins E Martins F, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol. 2011 ; 47 : 998-1003.
PubMed
P.60 掲載の参考文献
1) Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997 ; 15 : 103-9.
PubMed
2) Morrow GR, Hickok JT, Burish TG, et al. Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol. 1996 ; 19 : 199-203.
 
3) Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985 ; 3 : 1379-84.
PubMed
4) 日本癌治療学会, 編. 制吐薬適正使用ガイドライン 2015年10月. 第2版. 東京 : 金原出版 ; 2015.
 
5) Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015 ; 2015 : 595894.
PubMed
6) National Comprehensive Cancer Network (NCCN). NCCN Guidelines Antiemesis. Version 2. 2017.
 
7) Morrow GR, Roscoe JA, Hynes HE, et al. Progress in reducing anticipatory nausea and vomiting : a study of community practice. Support Care Cancer. 1998 ; 6 : 46-50.
PubMed
8) Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis : results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006 ; 17 : 20-8.
PubMed
9) Hesketh PJ, Kris MG, Basch E, et al. Antiemetics : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 : doi : 10.1200/JCO.2017.74.4789. [Epub ahead of print]
 
10) Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016 ; 27 (suppl 5) : v119-33.
 
11) Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 ; 375 : 134-42.
PubMed
12) Sekine I, Segawa Y, Kubota K, et al. Risk factors of chemotherapy-induced nausea and vomiting : index for personalized antiemetic prophylaxis. Cancer Sci. 2013 ; 104 : 711-7.
PubMed
13) Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000 ; 342 : 1554-9.
PubMed

[II] がん治療時に遭遇しやすい問題 : 感染対策

P.66 掲載の参考文献
1) Safdar N, Maki DG. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. Crit Care Med. 2002 ; 30 : 2632-5.
PubMed
2) Mermel LA, Allon M, Bouza E, et al. IDSA guidelines for intravascular catheter-related infection. Clin Infect Dis. 2009 ; 49 : 1-45.
 
3) Raad I, Hanna HA, Alakech B, et al. Differential time to positivity : a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004 ; 140 : 18-25.
PubMed
4) National Nosocomial Infections Surveillance System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004 ; 32 : 470-85.
PubMed
5) Tao F, Jiang R, Chen Y, et al. Risk factors for early onset of catheter-related bloodstream infection in an intensive care unit in China : a retrospective study. Med Sci Monit. 2015 ; 21 : 550-6.
 
6) Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis : 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 ; 62 : e1-50.
 
7) Sakihama T , Tokuda Y. Use of peripheral parenteral nutrition solutions as a risk factor for bacillus cereus peripheral venous catheter-associated bloodstream infection at a Japanese tertiary care hospital : a case-control study. Jpn J Infect Dis. 2016 ; 69 : 531-3.
 
P.73 掲載の参考文献
1) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 ; 52 : e56-93.
 
2) Klastersky J. Febrile neutropenia. Curr Opin Oncol. 1993 ; 5 : 625-32.
PubMed
3) 日本臨床腫瘍学会. 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 : 南江堂 ; 2012.
 
4) 日本癌治療学会. G-CSF適正使用ガイドライン 2013年版. 東京 : 金原出版 ; 2013.
 
5) Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 ; 64 : 328-40.
PubMed
6) Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 ; 106 : 2258-66.
PubMed
7) Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 up-date of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol. 2006 ; 24 : 3187.
 
8) Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 ; 47 : 8.
PubMed
9) NCCN Clinical Practice Guidelines in Oncology-Myeloid growth factors : version 1, 2012.
 
10) Haim N, Shulman K, Goldberg H, et al. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol. 2005 ; 22 : 229.
PubMed
11) Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 ; 106 : 2258-66.
PubMed
12) NCCN Clinical Practice Guidelines in Oncology-Myeloid growth factors : version 2. 2016.
 
P.79 掲載の参考文献
1) Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 ; 22 : 2918-26.
PubMed
2) 後藤慶子. 消化器症状に対するアプローチ・下痢. In : 山本昇, 他編. がん診療レジデントマニュアル. 第7版. 東京 : 医学書院 ; 2017. p.419-22.
 
3) National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
 
4) 松本主之, 藤澤律子, 河内修司, 他. 感染性腸炎-最近の動向と知見Clostridium difficile感染症. 胃と腸. 2008 ; 43 : 1629-36.
 
5) 大西健児, 相野田祐介, 今村顕史, 他. JAID/JSC感染症治療ガイドライン 2015-腸管感染症-. 日化療会誌. 2015 ; 64 : 31-65.
 
6) 大川清孝, 上田渉, 佐野弘治, 他. 感染性腸炎-最近の動向と知見 サイトメガロウイルス腸炎. 胃と腸. 2008 ; 43 : 1653-62.
 
7) 福島聡. 免疫チェックポイント阻害剤による有害事象. 日臨免疫会誌. 2016 ; 39 : 30-6.
 
P.87 掲載の参考文献
1) 日本呼吸器学会 薬剤性肺障害の診断・治療の手引き作成委員会, 編. 薬剤性肺障害の診断・治療の手引き. 大阪 : メディカルレビュー社 ; 2012.
 
2) Camus P, Fanton A, Bonniaud P, et al. Interstitial ling disease induced by drugs and radiation. Respiration. 2006 ; 71 : 301-26.
 
3) Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer : a cohort and nested case-control study. Am J Respir Crit Care Med. 2008 ; 177 : 1348-57.
PubMed
4) Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis : thin-section CT findings in 60 patients. Radiology. 2002 ; 224 : 852-60.
PubMed
5) Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008 ; 133 : 528-38.
PubMed
6) Rossi SE, Erasmus JJ, McAdams HP, et al. Pulmonary drug toxicity : radiologic and pathologic manifestation. Radiographics. 2000 ; 20 : 1245-59.
PubMed
7) Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003 ; 58 : 872-5.
PubMed
8) Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung disease. Respir Investig. 2012 ; 50 : 3-13.
PubMed
9) Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002 ; 165 : 378-81.
PubMed
10) Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998 ; 158 : 1680-4.
PubMed
11) Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med. 2004 ; 25 : 25-35.
PubMed
12) Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004 ; 25 : 53-64.
PubMed
13) Kenmotsu H, Sakai F, Kato T, et al. Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer : a study on risk factors using interim results of post-marketing all-case surveillance. ASCO. 2017.
 
14) 楠本昌彦, 岩澤多恵, 遠藤正浩, 他. 免疫チェックポイント阻害薬による肺障害の画像的特徴. 第57回日本呼吸器学会学術講演会. 2017.
 
15) Shibaki R, Akamatsu H, Yamamoto N, et al. Nivolmab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol. 2017 ; 28 : 1404-5.
 
16) 近藤有好. 薬剤による肺障害. 結核. 1999 ; 74 : 33-41.
 
17) Limper M, de Kruif MD, Duits AJ, et al. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect. 2010 ; 60 : 409-16.
PubMed
18) Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of β -D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia : a meta-analysis. Clin Microbiol Infect. 2013 ; 19 : 39-49.
 
19) Hou TY, Wang SH, Liang SX, et al. The screening performance of serum 1,3-beta-D-glucan in patients with invasive fungal diseases : a meta-analysis of prospective cohort studies. Plos One. 2015 ; 10 : e0131602.
PubMed
P.93 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会, 編. B型肝炎治療ガイドライン. 第3版. 2017.
 
2) European Association for the Study of the Liver. EASL 2017 clinical practice guideline on the management of hepatitis B virus infection. J Hepatol. 2017 ; 67 : 370-98.
 
P.97 掲載の参考文献
1) Ellis simonsen SM, Van orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect. 2006 ; 134 : 293-9.
 
2) Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis) : case-control study. BMJ. 1999 ; 318 : 1591-4.
PubMed
3) Teerachaisakul M, Ekataksin W, Durongwatana S, et al. Risk factors for cellulitis in patients with lymphedema : a case-controlled study. Lymphology. 2013 ; 46 : 150-6.
PubMed
4) Badger C, Seers K, Preston N, et al. Antibiotics/anti-inflammatories for reducing acute inflammatory episodes in lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 ; (2) : CD003143.
PubMed
5) Baddour LM, Bisno AL. Non-group A beta-hemolytic Streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med. 1985 ; 79 : 155-9.
 
6) Mortimer PS, Levick JR. Chronic peripheral oedema : the critical role of the lymphatic system. Clin Med (Lond). 2004 ; 4 : 448-53.
PubMed
7) 日本癌治療学会. がん診療ガイドライン. http://jsco-cpg.jp/guideline/31.html
 
8) Vignes S, Arrault M, Dupuy A. Factors associated with increased breast cancer-related lymphedema volume. Acta Oncol. 2007 ; 46 : 1138-42.
PubMed
9) Collins PS, Villavicencio JL, Abreu SH, et al. Abnormalities of lymphatic drainage in lower extremities : a lymphoscintigraphic study. J Vasc Surg. 1989 ; 9 : 145-52.
PubMed
10) Swartz MN. Clinical practice. Cellulitis. N Engl J Med. 2004 ; 350 : 904-12.
PubMed
11) Thomas K, Crook A, Foster K, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg : results of the UK Dermatology Clinical Trials Network's PATCH II trial. Br J Dermatol. 2012 ; 166 : 169-78.
 
12) Mihara M, Hara H, Furniss D, et al. Lymphaticovenular anastomosis to prevent cellulitis associated with lymphoedema. Br J Surg. 2014 ; 101 : 1391-6.
PubMed
13) Yamamoto T, Koshima I. Supermicrosurgical anastomosis of superficial lymphatic vessel to deep lymphatic vessel for a patient with cellulitis-induced chronic localized leg lymphedema. Microsurgery. 2015 ; 35 : 68-71.
PubMed
P.105 掲載の参考文献
1) 日本摂食嚥下リハビリテーション学会医療検討委員会. 摂食嚥下障害の評価 [簡易版] 2015. http://www.jsdr.or.jp/doc/doc_manual1.html (2017年10月9日引用)
 
2) 辻哲也, 編著. がんのリハビリテーションマニュアル. 東京 : 医学書院 ; 2011.
 
3) 日本がんリハビリテーション研究会, 編. がんのリハビリテーションベストプラクティス. 東京 : 金原出版 ; 2015.
 

[III] がん治療時に遭遇しやすい問題 : 腎・内分泌・代謝

P.110 掲載の参考文献
1) 日本腎臓学会, 日本癌治療学会, 日本臨床腫瘍学会, 日本腎臓病薬物療法学会, 編. がん薬物療法時の腎障害診療ガイドライン 2016. 東京 : ライフサイエンス出版 ; 2016.
 
2) Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003 ; 23 : 460-4.
PubMed
3) Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, et al. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol. 2011 ; 41 : 803-21.
PubMed
4) Tarrass F, Benmensour M, Bayla A. End-stage renal disease following carboplatin chemotherapy for a nasopharyngeal carcinoma. Ren Fail. 2007 ; 29 : 1049-51.
PubMed
5) Filewod N, Lipman ML. Severe acute tubular necrosis observed subsequent to oxaliplatin administration. Clin Kidney J. 2014 ; 7 : 68-70.
PubMed
6) Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985 ; 55 : 47-50.
 
7) Hamner RW, Verani R, Weinman EJ. Mitomycin-associated renal failure. Case report and review. Arch Intern Med. 1983 ; 143 : 803-7.
PubMed
8) Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexateinduced nephrotoxicity in patients with osteosarcoma. Cancer. 2004 ; 100 : 2222-32.
PubMed
9) Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006 ; 11 : 694-703.
PubMed
10) Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 1996 ; 348 : 578-80.
PubMed
11) Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol. 2009 ; 27 : 5350-5.
 
12) Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001 ; 12 : 1164-72.
PubMed
13) Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 ; 25 : 2464-72.
 
14) Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 ; 21 : 4042-57.
 
15) Fung MC, Storniolo AM, Nguyen B, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999 ; 85 : 2023-32.
 
16) De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 2008 ; 87 : 495-6.
PubMed
17) Glezerman IG, Pietanza MC, Miller V, et al. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011 ; 58 : 817-20.
PubMed
18) Michels J, Spano JP, Brocheriou I, et al. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009 ; 2 : 53-6.
PubMed
19) Izzedine H, Escudier B, Rouvier P, et al. Acute tubular necrosis associated with mTOR inhibitor therapy : a real entity biopsy-proven. Ann Oncol. 2013 ; 24 : 2421-5.
PubMed
20) Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 ; 90 : 638-47.
PubMed
P.119 掲載の参考文献
1) 日本腎臓学会・日本医学放射線学会・日本循環器学会, 編. 腎障害患者におけるヨード造影剤使用に関するガイドライン 2012. 1版. 東京 : 東京医学社 ; 2012.
 
2) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012 ; 2 : 1-138.
 
3) Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, et al. Contrast-induced nephropathy : basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017 ; 180 : 99-112.
PubMed
4) Manabe K, Kamihata H, Motohiro M, et al. Urinary liver-type fatty acidbinding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur J Clin Invest. 2012 ; 42 : 557-63.
PubMed
5) Ribitsch W, Schilcher G, Quehenberger F, et al. Neutrophil gelatinaseassociated lipocalin (NGAL) fails as an early predictor of contrast induced nephropathy in chronic kidney disease (ANTI-CI-AKI study). Sci Rep. 2017 ; 7 : 41300. doi : 10.1038/srep41300.
 
6) Eng J, Wilson RF, Subramaniam RM, et al. Comparative effect of contrast media type on the incidence of contrast-induced nephropathy : a systematic review and meta-analysis. Ann Intern Med. 2016 ; 164 : 417-24.
 
7) Nijssen EC, Rennenberg RJ, Esserts BA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING) : a prospective, randomized, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 ; 389 : 1312-22.
 
8) Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy : a systematic review and meta-analysis. Ann Intern Med. 2016 ; 164 : 406-16.
PubMed
9) Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy : a meta-analysis of 15 randomized controlled trials. Medicine. 2017 ; 96 : e7384. doi : 10.1097/MD.0000000000007384.
 
10) Cruz DN, Goh CY, Marenzi G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy : a systematic review. Am J Med. 2012 ; 125 : 66-78.
PubMed
P.125 掲載の参考文献
1) Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO. 2010 ; 21 : 1395-403. Epub 2010/02/02.
 
2) Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ case reports. 2016 ; 2016. Epub 2016/09/24.
 
P.132 掲載の参考文献
1) Samo J. Prevention and management of tumor lysis syndrome in adults with malignancy. J Adv Pract Oncol. 2013 ; 4 : 101-6.
 
2) Mirrakhimov AE, Ali AM, Khan M, et al. Tumor lysis syndrome in solid tumors : An up to date review of the literature. Rare Tumors. 2017 ; 13 : 5389.
 
3) Cario MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome in adults and children with malignant disease : an expert TLS pal consensus. Br J Hematol. 2010 ; 149 : 578-86.
 
4) 日本臨床腫瘍学会, 編. 腫瘍崩壊症候群 (TLS) 診療ガイダンス. 東京 : 金原出版 ; 2013. p.1-54.
 
5) 福原傑. 高カルシウム血症と腫瘍崩壊症候群. 日腎会誌. 2017 ; 59 : 598-605.
 
6) Wilson FP, Berns JS. Onco nephrology : tumor lysis syndrome. Clin J Am Soc Nephrol. 2012 ; 7 : 1730-9.
PubMed
7) Alkel N, Middeke JM, Schetelig J, et al. Prevention and treatment of tumor lysis syndrome, and the efficiency and role of rasburicase. Onco Targets Ther. 2017 ; 10 : 597-605.
 
P.141 掲載の参考文献
1) Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients : epidemiology, aetiology and differential diagnosis. Support Care Cancer. 2000 ; 8 : 192-7.
PubMed
2) Doshi SM, Shah P, Lei X, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012 ; 59 : 222-8.
PubMed
3) Gill G, Huda B, Boyd A, et al. Characteristics and mortality of severe hyponatraemia--a hospital-based study. Clin Endocrinol (Oxf). 2006 ; 65 : 246-9.
PubMed
4) Castillo JJ, Glezerman IG, Boklage SH, et al.The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 2016 ; 16 : 564.
 
5) Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012 ; 17 : 756-65.
PubMed
6) Berardi R, Santoni M, Rinaldi S, et al. Risk of hyponatraemia in cancer patients treated with targeted therapies : a systematic review and meta-analysis of clinical trials. PLoS One. 2016 ; 11 : e0152079.
PubMed
7) Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis. 2014 ; 21 : 7-17.
PubMed
8) Khan MI, Dellinger RP, Waguespack SG. Electrolyte disturbances in critically ill cancer patients : an endocrine perspective. J Intensive Care Med. 2017 Jan 1 : 885066617706650
 
9) Berardi R, Rinaldi S, Caramanti M, et al. Hyponatremia in cancer patients : time for a new approach. Crit Rev Oncol Hematol. 2016 ; 102 : 15-25.
PubMed
10) Spasovski R, Vanholder R, Allolio B, et al. Clinical practice guidelines on diagnosis and treatment of hyponatremia. Nephrol Dial Transplant. 2014 ; 29 (suppl 2) : ii1-ii39.
 
11) Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia ; expert panel recommendations. Am J Med. 2013 ; 126 (10 Suppl 1) : S1-42.
 
P.146 掲載の参考文献
1) Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2015 ; 351 : 373-9.
 
2) Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia : cloning and expression. Science. 1987 ; 237 : 893-6.
PubMed
3) Motokura T, Fukumoto S, Matsumoto T, et al. Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma. Ann Intern Med. 1989 ; 111 : 484-8.
PubMed
4) Breslau NA, McGuire JL, Zerwekh JE, et al. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med. 1984 ; 100 : 1-6.
PubMed
P.151 掲載の参考文献
1) 森川秋月, 羽田勝計. VII 特殊な病態における血糖管理周術期の血糖管理. 日臨. 2012 ; 70, Suppl 3 : 814-8.
 
2) 西澤誠. 併存疾患からみた治療と兼科のポイント消化管周術期の注意点. Medicina. 2014 ; 51 : 1428-32.
 
3) American diabetes association. Standards of medical care in diabetes-2017. 14. Diabetes care in the hospital. Diabetes Care. 2017 ; 40 : S120-7.
PubMed
4) Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004 ; 27 : 461-7.
 
5) Krikorian A, Ismail-Beigiet F, Moghissi ES, et al. Comparisons of different insulin infusion protocols : a review of recent literature. Curr Opin Clin Nutr Metab Care. 2010 ; 13 : 198-204.
 
6) Blaha J, Kopecky P, Matias M, et al. Comparisons of the three protocols for tight glycemic control in cardiac surgery patients. Diabetes Care. 2009 ; 32 : 757-61.
PubMed
P.157 掲載の参考文献
1) Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009 ; 94 : 709-28.
PubMed
2) Fukuda I, Hizuka N, Ishikawa Y, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006 ; 16 : 211-6.
PubMed
3) Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia : insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013 ; 34 : 798-826.
PubMed
4) Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia : a clinical review. J Clin Endocrinol Metab. 2014 ; 99 : 713-22.
PubMed

[IV] がん治療時に遭遇しやすい問題 : その他

P.163 掲載の参考文献
1) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 ; 37 : 2768-801.
 
2) 向井幹夫. がん診療における腫瘍循環器外来の役割. 医事新報. 2013 ; 4631 : 48-9.
Medical*Online
3) Yeh ET, Bickford CL. Cardiovascular complication of cancer therapy. Incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol. 2009 ; 53 : 2231-47.
PubMed
4) Plana JC, Galderinsi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 ; 27 : 911-39.
 
5) Varki A. Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood. 2007 ; 110 : 1723-9.
PubMed
6) Navi BB, Reiner AS, Kamel H et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017 ; 70 : 926-38.
 
7) Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies : focus on kinase inhibitors. J Am Coll Cardiol. 2015 ; 66 : 1160-78.
PubMed
P.169 掲載の参考文献
1) 太田富雄, 和賀志朗, 半田肇, 他. 意識障害の新しい分類法 試案-数量的表現 (III群3段階方式) の可能性. 脳神経外科. 1974 ; 2 : 623-7.
 
2) Galvin R, Brathen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010 ; 17 : 1408-18.
PubMed
3) 日本脳卒中学会 脳卒中医療向上・社会保険委員会 rt-PA (アルテプラーゼ) 静注療法指針改訂部会. rt-PA (アルテプラーゼ) 静注療法適正治療指針. 第2版. 2012年10月 (2016年9月一部改訂).
 
P.176 掲載の参考文献
1) Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 ; 122 : 1712-23.
PubMed
2) Horsted F, West J, Grainge MJ, et al. Risk of venous thromboembolism in patients with cancer : a systematic review and meta-analysis. Plos Med. 2012 ; 9 : e1001275.
 
3) Sakuma M, Fukui S, Nakamura M, et al. Cancer and pulmonary embolism thrombotic embolism, tumor embolism, and tumor invasion into a large vein. Circ J 2006 ; 70 : 744-9.
PubMed
4) Donnellan E, Kevane B, Bird BR, et al. Cancer and venous thromboembolic disease : from molecular mechanisms to clinical management. Curr Oncol. 2014 ; 21 : 134-43.
PubMed
5) Rak J, Yu JL, Luyendyk J, et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006 ; 66 : 10643-6.
PubMed
6) Le Gal GL, Righini M. Controversies in the diagnosis of venous thromboembolism. J Thromb Haemost. 2015 ; 13 Suppl 1 : 259-65.
 
7) Lyman GH, Khorana AA, Kuderer MM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013 ; 31 : 2189-204.
 
8) Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis : a systematic review and meta-analysis. Thromb Res. 2014 ; 134 : 1214-9.
PubMed
9) Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010 ; 125 : 490-3.
PubMed
10) Prandoni P, Lesing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 ; 100 : 3484-8.
 
P.182 掲載の参考文献
1) Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms : clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977 ; 56 : 1-37.
PubMed
2) Varki A. Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood. 2007 ; 110 : 1723-9.
PubMed
3) Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore). 1985 ; 64 : 16-35.
PubMed
4) Chen PC, Muo CH, Lee YT, et al. Lung cancer and incidence of stroke : a population-based cohort study. Stroke. 2011 ; 42 : 3034-9.
PubMed
5) Gon Y, Okazaki S, Terasaki Y, et al. Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016 ; 3 : 280-7.
PubMed
6) Gon Y, Sakaguchi M, Takasugi J, et al. Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke. Eur J Neurol. 2017 ; 24 : 503-8.
PubMed
7) Nam KW, Kim CK, Kim TJ, et al. Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant. J Stroke Cerebrovasc Dis. 2017 Aug 23.
 
8) Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol. 2014 ; 13 : 429-38.
PubMed
9) Ntaios G, Papavasileiou V, Milionis H, et al. Embolic strokes of undetermined source in the Athens stroke registry : a descriptive analysis. Stroke. 2015 ; 46 : 176-81.
PubMed
10) Geisler T, Poli S, Meisner C, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial) : rationale and study design. Int J Stroke. Epub 2016 Nov 23.
 
P.189 掲載の参考文献
1) 内富庸介. がんに対する通常の心理的反応とその基本的対応. In : 内富庸介, 小川朝生, 編. 精神腫瘍学. 1版. 東京 : 医学書院 ; 2011. p.43-50.
 
2) Cordi M, Rasch B. Increasing Slow-Wave Sleep by Hypnotic Suggetions. First Edition. Springer Publishing Company. 2016 ; p.611-20.
 
3) Greer JA, MacDonald J, Traeger L. Anxiety Disorders. In : Holland JG, Brietbart WS, Butow PN, et al. Editors. Psycho-Oncology. 3rd ed. Oxford University Press. 2015 ; p.296-303.
 
4) Wilson KG, ChoChinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manege. 2007 ; 33 : 118-29.
 
5) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Washington, DC. American Psychiatric Association Press ; 2013.
 
6) 清水研. うつ病, 適応障害. In : 内富庸介, 小川朝生, 編. 精神腫瘍学. 1版. 東京 : 医学書院 ; 2011. p.96-108.
 
7) Li M, Hales S, Rodin G. Adjustment Disorders. In : Holland JG, Brietbart WS, Butow PN, et al. Editors. Psycho-Oncology. 3rd ed. Oxford University Press ; 2015. p.274-88.
 
P.195 掲載の参考文献
1) 宮本雅之, 平田幸一. 睡眠関連運動障害群 (SRMDs). 睡眠医療. 2015 ; 9 : 175-84.
 
2) 野村哲志, 中島健二. Restless legs症候群の疫学. In : 日本神経治療学会治療指針作成委員会, 編. 標準的神経治療 : Restless legs症候群. 神経治療. 2012 ; 29 : 81-4.
 
3) 小池茂文. 二次性Restless legs症候群. In : 日本神経治療学会治療指針作成委員会, 編. 標準的神経治療 : Restless legs症候群. 神経治療. 2012 ; 29 : 90-4.
 
4) Ekbom KA. Restless legs syndrome. Acta Med Scand. 1945 ; 158 (suppl) : 4-12.
 
5) Nordlander NB. Therapy in restless legs. Acta Med Scand. Suppl. 1953 ; 145 : 453-7.
 
6) Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000 ; 54 : 1698-700.
PubMed
7) Ruottinen HM, Partinen M, Hubin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology. 2000 ; 54 : 502-4.
 
8) 小池茂文. レストレスレッグス症候群治療薬. 月刊薬事. 2014 ; 56 : 57-62.
 
9) Lin SC, Kaplan J, Burger CD, et al. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc. 1998 ; 73 : 497-500.
PubMed
10) Happe S, Trenkwalder C, et al. Role of dopamine receptor agonists in the treatment of restless legs syndrome.CNS Drugs. 2004 ; 18 : 27-36.
PubMed
11) Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome : a placebo-controlled crossover trial. Neurology. 2004 ; 62 : 1405-7.
PubMed
12) Merlino G, Serafini A, Young JJ, et al. Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome. Curr Opin Investing Drugs. 2009 ; 10 : 91-102.
 
13) Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome : report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012 ; 19 : 1385-96.
 

[V] がん治療後の問題

P.201 掲載の参考文献
1) Wu VC, Huang TM, Lai CF, et al. Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney Int. 2011 ; 80 : 1222-30.
PubMed
2) Horne KL, Packington R, Monaghan J, et al. Three-year outcomes after acute kidney injury : results of a prospective parallel group cohort study. BMJ Open. 2017 ; 7 : e015316.
 
3) Bhat ZY, Cadnapaphornchai P, Ginsburg K, et al. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury : an observational cohort study. PLoS One. 2015 ; 10 : e0142225.
PubMed
4) Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016 ; 11 : 1173-9.
PubMed
5) Kim CS, Bae EH, Ma SK, et al. Impact of transient and persistent acute kidneyinjury on chronic kidney disease progression and mortality after gastric surgery for gastric cancer. PLoS One. 2016 ; 11 : e0168119.
 
6) Siew ED, Parr SK, Abdel-Kader K, et al. Predictors of recurrent AKI. J Am Soc Nephrol. 2016 ; 27 : 1190-200.
 
7) Thakar CV, Christianson A, Himmerfarb J, et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011 ; 6 : 2567-72.
PubMed
8) Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014 ; 371 : 58-66.
PubMed
9) Sawhney S, Mitchell M, Marks A, et al. Long-term prognosis after acute kidney injury (AKI) : what is the role of baseline kidney function and recovery? A systematic review. BMJ Open. 2015 ; 5 : e006497.
PubMed
10) Villeneuve PM, Clark EG, Sikora L, et al. Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit : a systematic review. Intensive Care Med. 2016 ; 42 : 137-46.
PubMed
11) AKI (急性腎障害) 診療ガイドライン 2016. 東京 : 東京医学社 ; 2016. p.70-1.
 
12) Isshiki R, Asada T, Sato D, et al. Association of urinary neutrophil gelatinaseassociated lipocalin with long-term renal outcomes in ICU survivors : a retrospective observational cohort study. Shock. 2016 ; 46 : 44-51.
PubMed
P.208 掲載の参考文献
1) Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006 ; 24 : 5305-12.
PubMed
2) 日本乳癌学会診療ガイドライン委員会. アロマターゼ阻害薬使用患者における骨粗鬆症の予防・治療にビスフォスフォネートやデノスマブは勧められるか. In : 日本乳癌学会, 編. 科学的根拠に基づく乳癌診療ガイドライン 1 治療編. 東京 : 金原出版 ; 2015. p.178-80.
 
3) 前立腺癌診療ガイドライン2016年版作成委員. ホルモン療法にともなう有害事象およびその対策にはどのようなものが推奨されるか? In : 日本泌尿器科学会, 編. 前立腺癌診療ガイドライン 2016年版. 大阪 : メディカルレビュー社 ; 2016. p.214-8.
 
4) Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer duruing the first 2 years of androgen suppression. J Urol. 2006 ; 175 : 1679-83.
PubMed
5) Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 ; 352 : 154-64.
PubMed
6) 骨粗鬆症の予防と治療ガイドライン作成委員会. 骨粗鬆症の診断. In : 骨粗鬆症の予防と治療ガイドライン作成委員会, 編. 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015. p.26-9.
 
7) Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer : a randomized trial. Ann Intern Med. 2007 ; 146 : 416-24.
 
8) Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropinreleasing hormone agonist-induced bone loss in men with prostate cancer : a randomized controlled trial. J Clin Endocrinol Metab. 2004 ; 89 : 3841-6.
PubMed
9) Smith MR, Egerdin B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 ; 361 : 745-55.
 
10) Hillner BE, Ingel JN, Chlebowski RT, et al. American Society of Clinicl Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 ; 21 : 4042-57.
 
11) Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients : ESMO Clinical Practice Guidelines. Ann Oncol. 2014 ; 25 (Supple 3) : 124-37.
 
P.215 掲載の参考文献
1) Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits : mechanisms, findings, and potential interventions. Palliat Support Care. 2007 ; 5 : 273-80.
PubMed
2) Ahles TA, Root JC, Ryan EL. Cancer-and cancer treatment-associated cognitive change : an update on the state of the science. J Clin Oncol. 2012 ; 30 : 3675-86.
PubMed
3) Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls : an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2016 : JCO2016685856. [Epub ahead of print]
 
4) Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007 ; 7 : 192-201.
PubMed
5) Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013 ; 30 Suppl : S109-16.
 
6) Wang L, Apple AC, Schroeder MP, et al. Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls. Cancer. 2016 ; 122 : 258-68.
PubMed
7) Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016 ; 2 : 185-92.
PubMed
8) Von Ah D, Storey S, Jansen CE, et al. Coping strategies and interventions for cognitive changes in patients with cancer. Semin Oncol Nurs. 2013 ; 29 : 288-99.
PubMed
9) Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change : results of a waitlist control trial. Psychooncology. 2012 ; 21 : 176-86.
PubMed
10) Bray VJ, Dhillon HM, Bell ML et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol. 2017 ; 35 : 217-25.
PubMed
11) Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009 ; 115 : 2605-16.
PubMed
12) Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer : a double-blind, randomised, cross-over trial. Palliat Med. 2009 ; 23 : 731-8.
 
13) Shaw EG, Rosdhal R, D'Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients : effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006 ; 24 : 1415-20.
PubMed
14) Jatoi A, Kahanic SP, Frytak S, et al. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients : preliminary results and suggestions for future study designs. Support Care Cancer. 2005 ; 13 : 66-9.
PubMed
P.223 掲載の参考文献
1) 清野精彦, 富田喜文, 長野具雄, 他. 抗悪性腫瘍薬による心筋症. 日循専門医誌. 1996 ; 4 : 337-42.
 
2) Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction : time to recognize a new entity. J Clin Oncol. 2005 ; 23 : 2900-2.
PubMed
3) Abdel-Qadir H, Amir E, Thavendiaranathan P. Prevention, detection, and management of chemotherapy-related cardiac dysfunction. Can J Cardiol. 2016 ; 32 : 871-80.
 
4) 清野精彦. がん化学療法による心毒性-AnthracyclineおよびTrastuzumab心毒性について. 心臓. 2014 ; 46 : 322-9.
 
5) 青野真弓, 實川東洋, 福田恵子, 他. がん化学療法における心筋障害の病態と対策-アントラサイクリン心筋症など. 呼吸と循環. 2016 ; 64 : 849-57.
 
6) Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 ; 17 : 3333-56.
 
7) Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011 ; 57 : 2263-70.
PubMed
8) Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults : early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006 ; 7 : 141-6.
PubMed
9) Seino Y, Otsuka T. Expanding the role of cardiac biomarkers-natriuretic peptides and troponins. Hypertens Res. 2015 ; 38 : 11-2.
PubMed
10) Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 ; 351 : 145-53.
PubMed
11) Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006 ; 114 : 2474-81.
PubMed
12) Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy : clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 ; 55 : 213-20.
PubMed
P.230 掲載の参考文献
1) Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction. 2012 ; 144 : 153-63.
PubMed
2) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 ; 31 : 2500-10.
 
3) Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012 ; 48 : 3355-77.
PubMed
4) Hideyuki I, Yuriko I, Teresa KW. Pregnancy and Cancer. Glob J Reprod Med. 2017 ; 1 : 555566.
 
5) Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors : probable effects of abdominal irradiation. International journal of cancer. 1989 ; 43 : 399-402.
PubMed
6) Signorello LB, Mulvihill JJ, Green DM, et al. Stillbirth and neonatal death in relation to radiation exposure before conception : a retrospective cohort study. Lancet. 2010 ; 376 : 624-30.
 
7) von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011 ; 284 : 427-35.
PubMed
8) 日本がん治療学会. 総論CQ1挙児希望を有するがん患者に対して, どのような妊孕性に関連する情報を提供するべきか? In : 日本癌治療学会, 編. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京 : 金原出版 ; 2017. p.22-4.
 
9) Coccia PF, Pappo AS, Altman J, et al. Adolescent and young adult oncology, version 2. 2014. J Nat Comp Canc Netw. 2014 ; 12 : 21-32 ; quiz 32.
 
10) Niemasik EE, Letourneau J, Dohan D, et al. Patient perceptions of reproductive health counseling at the time of cancer diagnosis : a qualitative study of female California cancer survivors. J Cancer Surviv. 2012 ; 6 : 324-32.
PubMed
P.243 掲載の参考文献
1) Pachman DR, Barton DL, Watson JC, et al. Chemotherapy-induced peripheral neuropathy : prevention and treatment. Clin Phrmacol Ther. 2011 ; 90 : 377-87.
PubMed
2) 厚生労働省. 重篤副作用疾患別対応マニュアル. 2009.
 
3) Argyrion AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults : a comprehensive update of the literature. Cancer Manag Res. 2014 ; 6 : 135-47.
 
4) Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1 : a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006 ; 24 : 394-400.
 
5) 篠崎英司. 抗がん剤誘発末梢神経障害とその対処. Pain Clinic. 2010 ; 31 ; 859-67.
 
6) 荒川和彦, 鳥越一宏, 葛巻直子, 他. 抗がん剤による末梢神経障害の特徴とその作用機序. 日緩和医療薬誌. 2011 ; 4 : 1-13.
 
7) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン作成ワーキンググループ, 編. 神経障害性疼痛薬物療法ガイドライン. 改訂第2版. 東京 : 真興交易医書出版部 ; 2011.
 
P.248 掲載の参考文献
1) Charnsangavej C, Carrasco CH, Wallace S, et al. Stenosis of the vena cava : preliminary assessment of treatment with expandable metallic stents. Radiology. 1986 ; 161 : 295-8.
PubMed
2) Kishi K, Sonomura T, Mitsuzane K, et al. Self-expandable metallic stent therapy for superior vena cava syndrome : clinical observations. Radiology. 1993 ; 189 : 531-5.
PubMed
3) Nagata T, Makutani S, Uchida H, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc intervent radiol. 2007 ; 30 : 959-67.
PubMed
P.253 掲載の参考文献
1) 高橋三郎, 大野裕, 監訳. DSM-5 精神疾患の診断・統計マニュアル. 1版. 東京 : 医学書院 ; 2014. p.160-285.
 
2) Uchitomi Y, Mikami I, Nagai K, et al. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. J Clin Oncol. 2003 ; 21 : 69-77.
PubMed
3) Ozga M, Aghajanian C, Myers-Virtue S, et al. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015 ; 13 : 1771-80.
PubMed
4) 勝俣範之, 監訳. がんサバイバー 医学・心理・社会的アプローチでがん治療を結いなおす. 1版. 東京 : 医学書院 ; 2012. p.28-40.
 
5) Arnaboldi P, Lucchiari C, Santoro L, et al. PTSD symptoms as a consequence of breast cancer diagnosis : clinical implications. Springerplus. 2014 ; 3 : 392. doi : 10.1186/2193-1801-3-392.
 
6) Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients : associated and predictive factors. J Clin Oncol. 2004 ; 22 : 1957-65.
PubMed
7) 大西秀樹, 編. 専門医のための精神科臨床リュミエール 24 サイコオンコロジー. 1版. 東京 : 中山書店 ; 2010. p.13-58.
 
8) Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016 ; 34 : 611-35.
 
9) 内富庸介, 大西秀樹, 藤澤大介, 監訳. がん患者心理療法ハンドブック. 1版. 東京 : 医学書院 ; 2013. p.3-79.
 
P.259 掲載の参考文献
1) Szuba A, Rockson SG. Lymphedema : classification, diagnosis and therapy. Vasc Med. 1998 ; 3 : 145-56.
PubMed
2) Shaitelman SF, Cromwell KD, Rasmussen JC, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015 ; 65 : 55-81.
PubMed
3) 樋口友紀, 中西陽子, 廣瀬規代美, 他. 手術療法を受けたがん患者に対するリンパ浮腫ケアの課題. Kitakanto Med J. 2009 ; 59 : 43-50.
Medical*Online
4) International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2003 Consensus Document of the International Society of Lymphology. Lymphology. 2003 ; 36 : 84-91.
PubMed
5) Unno N, Inuzuka K, Suzuki M, et al. Preliminary experience with a novel fluorescence lymphography using indocyanine green in patients with secondary lymphedema. J Vasc Surg. 2007 ; 45 : 1016-21.
PubMed
6) 一般社団法人リンパ浮腫療法士認定機構. リンパ浮腫の最近の治療 : 方法, 手技について. リンパ浮腫診断治療指針 2013. Medical Tribune. 2013 ; 45-57.
 

書評

最近チェックした商品履歴

Loading...